Delivering specific antibody against the SMC2 intracellularly is an effective strategy, which aims to reduce cancer malignancy by targeting cancer stem cells (CSC), the tumoral subpopulation responsible of tumor recurrence and metastasis [56]. This evidence concerns the gene SMC2 and neoplasm.